The Study and Development of FDA Drug Risk Management Plan in View of Specific Drug
LI Shu -fang1, PAN Wen -hao2
1.The Fengtian Hospital of Shenuyang Medical University, Liaoning Shenyang 110024, China; 2.The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Liaoning Shenyang 110032, China
LI Shu -fang, PAN Wen -hao. The Study and Development of FDA Drug Risk Management Plan in View of Specific Drug [J]. Chinese Journal of Pharmacovigilance, 2013, 10(3): 144-147.
[1] FDA. Risk Evaluation and Mitigation Strategies(REMS) and Opioid AnalgesicsWebinar. Part II-OpioidAnalgesics[EB/OL]. [2009-11-20].http://www.fda.gov/Drugs/DrugSafety/InformationbyDrug-Class/ucm163655.htm. [2] FDA.Questions and Answers: FDA approves a Risk Evaluation and MitigationStrategy(REMS) forExtended-ReleaseandLong-Acting(ER/LA) Opioid Analgesics[EB/OL]. [2012-07-14].http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm. [3] FDA.ER/LAOpioidAnalgesicsREMS[EB/OL].[2012-08-28].http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf. [4] FDA.Oxycontin:BalancingRisksandBenefits[EB/OL]. [2002-02-12].www.fda.gov/NewsEvents/Testimony/ucm115180.htm-14k-2009-03-09-Cached. [5] FDA.Risk Evaluation and Mitigation Strategies(REMS) and Opioid Analgesics Webinar. Part I-Introduction[EB/OL]. [2009-11-20].http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163655.htm. [6] FDA.Risk Evaluation and Mitigation Strategies (REMS) and Opioid Analgesics Webinar. Part IV-Next Steps[EB/OL]. [2009-11-20].http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm163655.htm. [7] FDA.OpioidDrugApprovals(2009)[EB/OL].[2012-07-09].http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm187976.htm. [8] FDA.Opioid Drugs and Risk Evaluation and Mitigation Strategies(REMS): November 2009 Update[EB/OL]. [2010-09-23].http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm226958.htm. [9] FDA. FDA introduces new safety measures for extended-release and long-acting opioid medications Strategy emphasizes education for prescribers, patients on highly potent pain relievers [EB/OL].[2012-07-09 ] .http: //www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm.
